AAAAAA
Results:
1-11
|
Results: 11
Authors:
Barnes, N
Wei, LX
Reiss, TF
Leff, JA
Shingo, S
Yu, C
Edelman, JM
Citation: N. Barnes et al., Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function, RESP MED, 95(5), 2001, pp. 379-386
Authors:
Maspero, JF
Duenas-Meza, E
Volovitz, B
Daza, CP
Kosa, L
Vrijens, F
Leff, JA
Citation: Jf. Maspero et al., Oral montelukast versus inhaled beclomethasone in 6-to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy, CURR MED R, 17(2), 2001, pp. 96-104
Authors:
Simons, FER
Villa, JR
Lee, BW
Teper, AM
Lyttle, B
Aristizabal, G
Laessig, W
Schuster, A
Perez-Frias, J
Sekerel, BE
Menten, J
Leff, JA
Citation: Fer. Simons et al., Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study, J PEDIAT, 138(5), 2001, pp. 694-698
Authors:
Bjermer, L
Bisgaard, H
Bousquet, J
Fabbri, LM
Greening, A
Haahtela, T
Holgate, ST
Picado, C
Leff, JA
Citation: L. Bjermer et al., Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (theIMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial), RESP MED, 94(6), 2000, pp. 612-621
Authors:
Dockhorn, RJ
Baumgartner, RA
Leff, JA
Noonan, M
Vandormael, K
Stricker, W
Weinland, DE
Reiss, TF
Citation: Rj. Dockhorn et al., Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients, THORAX, 55(4), 2000, pp. 260-265
Authors:
Volovitz, B
Duenas-Meza, E
Chmielewska-Szewczyk, DA
Kosa, L
Astafieva, NG
Villaran, C
Pinacho-Daza, C
Laurenzi, M
Jasan, J
Menten, J
Leff, JA
Citation: B. Volovitz et al., Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: A multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma, CURR THER R, 61(7), 2000, pp. 490-506
Authors:
Lofdahl, CG
Reiss, TF
Leff, JA
Israel, E
Noonan, MJ
Finn, AF
Seidenberg, BC
Capizzi, T
Kundu, S
Godard, P
Citation: Cg. Lofdahl et al., Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients, BR MED J, 319(7202), 1999, pp. 87-90
Authors:
Diamant, Z
Grootendorst, DC
Veselic-Charvat, M
Timmers, MC
De Smet, M
Leff, JA
Seidenberg, BC
Zwinderman, AH
Peszek, I
Sterk, PJ
Citation: Z. Diamant et al., The effect of montelukast (Mg-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma, CLIN EXP AL, 29(1), 1999, pp. 42-51
Authors:
Pizzichini, E
Leff, JA
Reiss, TF
Hendeles, L
Boulet, LP
Wei, LX
Efthimiadis, AE
Zhang, J
Hargreave, FE
Citation: E. Pizzichini et al., Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial, EUR RESP J, 14(1), 1999, pp. 12-18
Authors:
Villaran, C
O'Neill, SJ
Helbling, A
van Noord, JA
Lee, TH
Chuchalin, AG
Langley, SJ
Gunawardena, KA
Suskovic, S
Laurenzi, M
Jasan, J
Menten, J
Leff, JA
Citation: C. Villaran et al., Montelukast versus salmeterol in patients with asthma and exercise-inducedbronchoconstriction, J ALLERG CL, 104(3), 1999, pp. 547-553
Authors:
Leff, JA
Citation: Ja. Leff, Leukotriene modifiers as novel therapeutics in asthma, CLIN EXP AL, 28, 1998, pp. 147-153
Risultati:
1-11
|